SGLT2 Inhibitors vs GLP-1 Drugs: Kidney Study Results

If you have type 2 diabetes and want to protect your kidneys, the first direct comparison between SGLT2 inhibitors and GLP-1 receptor agonists offers a useful answer: SGLT2 inhibitors performed better on chronic kidney disease and acute kidney injury outcomes, while GLP-1 drugs had an edge on albuminuria and all-cause mortality. That is not a tie. It is also not a clean knockout.

The practical question is rarely "Which drug wins?" A better question is which risks matter most for a particular patient, and whether the drugs can be used together safely and appropriately. Kidney disease does not grade on a single exam.

The first head-to-head comparison split the scorecard

In a 2026 Danish target-trial emulation by Jensen et al., researchers compared 36,279 metformin-treated adults with type 2 diabetes who started an SGLT2 inhibitor with 18,782 who started a GLP-1 receptor agonist. The nationwide registry analysis included 55,061 people and used inverse-probability weighting to make the groups more comparable. Follow-up extended through October 2024.

SGLT2 inhibitors had the lower five-year risk on the study's coprimary CKD endpoint: 6.7% versus 8.2% with GLP-1 receptor agonists. That produced a relative risk of 0.81 (95% CI, 0.76–0.87) and an absolute risk difference of −1.5 percentage points (95% CI, −2.0 to −1.0). In other words, the relative advantage was 19%, but the observed absolute difference over five years was 1.5 cases per 100 people.

SGLT2 inhibitors also had fewer acute kidney injury events. The mean cumulative count was 25.2 per 100 people (95% CI, 24.4–26.1), compared with 28.7 per 100 for GLP-1 receptor agonists (95% CI, 27.4–30.0). The mean cumulative count ratio was 0.88 (95% CI, 0.83–0.93).

Those are meaningful findings, especially for preventing kidney disease before it becomes established. The SGLT2 inhibitor advantage was most pronounced among people without preexisting CKD. That subgroup pattern limits any attempt to treat the result as proof that SGLT2 inhibitors outperform GLP-1 drugs equally in patients who already have CKD.

The same study complicates the simple "SGLT2 first, case closed" story. Secondary analyses directionally favored GLP-1 receptor agonists for albuminuria and all-cause mortality. Albuminuria is a useful marker of kidney damage, but it is still a surrogate outcome. All-cause mortality is a patient outcome. The available report describes these GLP-1 advantages as slight and consistent, but does not provide the numerical effect estimates needed to judge their size.

The Danish comparison supports an SGLT2 inhibitor advantage for its specific CKD composite and acute kidney injury outcomes. It does not establish broad superiority across every kidney, cardiovascular, and survival outcome.

What randomized GLP-1 evidence adds

Observational comparisons can reduce confounding; they cannot erase it. Doctors may prescribe SGLT2 inhibitors and GLP-1 drugs to patients with different kidney, cardiovascular, weight, and access profiles. Jensen and colleagues used a careful target-trial approach, but residual confounding and prescribing-channel bias remain possible. The cohort also consisted of metformin-treated Danish patients who initiated treatment between 2014 and 2020, so it does not neatly represent every current patient or health system.

Randomized evidence gives GLP-1 receptor agonists a substantial role in established CKD. A 2025 meta-analysis by Sasaki et al. combined 19 trials with 90,882 participants and a mean follow-up of 25.9 months. GLP-1 receptor agonists reduced the composite primary renal outcome by 19% (RR, 0.81; 95% CI, 0.73–0.89), renal functional decline by 12% (RR, 0.88; 95% CI, 0.81–0.95), and microalbuminuria by 24% (RR, 0.76; 95% CI, 0.71–0.82). They also reduced all-cause mortality by 14% (RR, 0.86; 95% CI, 0.82–0.91) and major adverse cardiovascular events by 15% (RR, 0.85; 95% CI, 0.81–0.90).

The important limit appears at the endpoint patients and nephrologists care about most: kidney failure. The pooled estimate was RR 0.86 (95% CI, 0.71–1.05). Because the confidence interval crosses 1.0, this meta-analysis did not show a statistically significant reduction in progression to kidney failure. GLP-1 drugs can slow measures of kidney decline and reduce albuminuria; this evidence does not yet confirm that they prevent dialysis or kidney failure.

A 2025 systematic review and meta-analysis by Felix et al. focused more narrowly on 18,042 people with type 2 diabetes and established CKD across 10 randomized trials. It included the 3,533-participant FLOW trial of semaglutide, which followed patients for a median of 3.4 years. The review found reductions in kidney-specific composite outcomes, cardiovascular events, and mortality, including among people with stage 3b CKD, defined as an eGFR of 30–45 mL/min/1.73 m².

That is reassuring for people who already have moderate CKD, but it does not mean every GLP-1 drug produces identical results. The CKD-specific evidence is heavily influenced by FLOW and semaglutide, while individual GLP-1 agents have different cardiorenal safety profiles in a 2025 network meta-analysis. Background SGLT2 inhibitor use also reached 15.7% in FLOW, which makes it harder to isolate a pure GLP-1-only kidney effect.

Albuminuria stacking has trial support

If albuminuria persists despite an SGLT2 inhibitor, adding a nonsteroidal mineralocorticoid receptor antagonist such as finerenone has a stronger evidence base than simply hoping the first drug works harder.

A 2023 network meta-analysis by Morita et al. included 17 randomized trials and 34,412 people with type 2 diabetes and a urine albumin-to-creatinine ratio of at least 30 mg/g. Compared with placebo, SGLT2 inhibitors lowered UACR by 31.03 mg/g (95% CI, −33.72 to −28.35), and mineralocorticoid receptor antagonists lowered it by 32.97 mg/g (95% CI, −36.27 to −29.68). The combination lowered UACR by 65.22 mg/g (95% CI, −72.47 to −57.97).

That combination result was roughly double either class alone. It also showed an incremental reduction of 34.19 mg/g over SGLT2 inhibitor monotherapy (95% CI, −41.08 to −27.30). Albuminuria reduction matters, but it remains a surrogate. This network analysis did not directly compare SGLT2 inhibitor plus finerenone against a GLP-1 receptor agonist, so it cannot show that the combination matches or exceeds the GLP-1 albuminuria advantage seen in the Danish comparison.

The 2025 CONFIDENCE trial analysis added a clinically relevant detail: starting finerenone and empagliflozin together produced additive albuminuria reduction in people with type 2 diabetes and CKD, and that effect persisted whether or not patients were already taking a GLP-1 receptor agonist. This comes closest to evidence for three-drug stacking, but it was a subgroup analysis rather than a trial designed to test triple therapy on kidney failure.

Why triple therapy remains an inference

A 2024 analysis by Neuen et al. modeled lifetime cardiovascular, kidney, and mortality benefits of combining an SGLT2 inhibitor, a GLP-1 receptor agonist, and a nonsteroidal MRA in people with type 2 diabetes and albuminuria. The model projected additive benefits compared with conventional care. Models can help estimate the value of a plausible strategy; they cannot prove a treatment prevents dialysis, heart attacks, or death in the way a prospective randomized trial can.

No completed randomized trial has assigned patients to this triple combination with kidney failure as the primary endpoint. Medication burden, cost, gastrointestinal adverse effects with GLP-1 drugs, volume-related concerns with SGLT2 inhibitors, and potassium monitoring with finerenone all belong in the real-world decision.

One further uncertainty concerns body size. A 2025 meta-analysis by Zhang et al. found that GLP-1 receptor agonists and tirzepatide reduced heart-failure risk in obese, but not non-obese, people with cardiovascular or kidney disease. It did not establish the same BMI-dependent pattern for kidney outcomes. Still, it is a reason to avoid assuming that every person with CKD receives the same cardiorenal benefit.

The bottom line

For type 2 diabetes without established CKD, the direct Danish comparison favors SGLT2 inhibitors for lowering the measured risk of CKD progression and acute kidney injury. For people with established CKD, the comparative advantage narrowed, while randomized evidence supports GLP-1 receptor agonists for composite kidney outcomes, slower kidney-function decline, cardiovascular events, and mortality.

The evidence points toward complementary treatment, not a winner-take-all contest. An SGLT2 inhibitor has the stronger track record for hard kidney-risk management; a GLP-1 receptor agonist adds metabolic, cardiovascular, and survival benefits; finerenone can further reduce albuminuria. Whether all three prevent more kidney failure than well-chosen dual therapy remains unproven. That is a decision for a clinician who can weigh eGFR, albuminuria, potassium, cardiovascular disease, weight, tolerability, cost, and the patient sitting in front of them.